37 results about "Cells heart" patented technology

Provided herein are methods of preparing an engineered heart valve for implantation into a subject in need (e.g., a pediatric patient). For example, a porcine pulmonary valve can be decellularized and then recellularized with cells from the subject. Hydrogels can be used to facilitate cell delivery and growth within the sub-endothelial layer (e.g., spongiosa) of a heart valve, which is essential for long-term success of the implantation.

A heart organoid of at least 60% cardiac cells irrespective of optional additional cells of a vascular system of the organoid, or including at least 50% cardiac cells; wherein the cardiac cells surround an inner cavity, wherein the cardiac cells are selected from the group of cardiomyocytes, endocardial cells and epicardial cells, and wherein the heart organoid includes cardiomyocytes or endocardial cells that directly face the inner cavity, a method for the generation of such a tissue model and uses thereof.

The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein identified using a high-throughput sequencing screen or rational design. In particular, the disclosure provides AAV5 virions and capsid proteins with increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.

A computational system and method for digital modeling of cardiac cell membrane electrophysiology is disclosed. The system generates a digital model representing the cell membrane as a dielectric lipid bilayer comprising a capacitor element and a resistor element, where the resistor element is emulated by a plurality of ion channels. The system calculates cell membrane potential based on intracellular and extracellular concentrations of key ions, such as Na+, K+, Ca2+, and Cl-, using the Goldman-Hodgkin-Katz equation. Generation of cellular membrane action potentials is simulated by modeling the opening and closing of voltage-gated ion channels in response to triggering events. The model provides dynamic visualizations of the distinct phases of the action potential, including depolarization and repolarization, offering a high-fidelity tool for research and for enhancing the realism of training simulations in electrophysiology procedures.

This disclosure relates generally to methods of screening and preparing cardiac cell therapies for potency (e.g., cardiac cell function).

The present disclosure describes ultrasound-based methods for facilitating the selective transduction of cardiac cells with therapeutic AAV vectors in vivo.

The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein. In particular, the disclosure provides AAV9 virions with engineered AAV9 capsid, AAV5 / 9 chimeric capsid or combinatory capsid that achieves increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.

A computational system and method for digital modeling of biochemical reactions within cardiac cells are disclosed. The system comprises processors and a computer-readable storage device with instructions to maintain biological data related to cardiac cell reactions and receive user selections via a user interface to configure a simulation. The user can select a cardiac cell class, and functions to load cellular components, generate enzyme activity, load specific enzymes, and perform enzymatic reactions. The system performs in silico experiments, predicts new biological data, and compiles this into configuration data. An enzyme activity model is generated and simulated under various conditions, including user-defined enzymatic dysregulation, to replicate and study cardiac physiology and pathology. The results, such as changes in energy metabolism parameters like glucose consumption and ATP usage, are outputted. The system provides a detailed and interactive platform for research and education in cardiac electrophysiology and disease.

The invention discloses a preparation method and application of mesoderm-sourced heart mesenchymal stem cells, mesoderm-sourced CMSC is induced by hPSC, the differentiation path of the mesoderm-sourced CMSC is strictly limited through a specific induction culture solution, and the mesoderm-sourced CMSC is obtained after the mesoderm-sourced CMSC is subjected to the stages of mesoderm progenitor cells, cardiac progenitor cells and epicardial progenitor cells in sequence, and the mesoderm-sourced CMSC is clear in source and low in heterogeneity. The cardiac micro-tissue formed by assembling the cardiac muscle cells, the endothelial cells and the CMSC from the hPSC shows remarkable advantages in the aspects of cardiac micro-tissue polymerization capability and cardiac muscle cell maturation promotion, and related functions and repeatability of the model are improved; the requirements of a large-scale heart micro-tissue detection platform can be met; a new seed cell source is provided for cell therapy of cardiovascular diseases; a novel and high-quality cell source is provided for heart disease modeling and clinical transformation, especially for constructing heart micro-tissues, supporting heart cell transplantation, cell therapy of cardiovascular diseases and the like.

The utility model discloses a micro-fluidic chip culture box for nerve and heart co-culture, and relates to the technical field of cell co-culture. Comprising a box body and a box cover, a nutrient solution supply system, a liquid medicine supply system, a micro-fluidic chip and a waste liquid recovery system are arranged in the box body, a heart cell culture area and a nerve cell culture area are arranged on the micro-fluidic chip, and the heart cell culture area is connected with the nerve cell culture area through a controllable micro-channel; the nutrient solution supply system is used for providing nutrient solution for the heart cell culture area and the nerve cell culture area, the liquid medicine supply system is used for providing liquid medicine for the heart cell culture area and the nerve cell culture area, and the waste liquid recovery system is used for collecting waste liquid of the heart cell culture area and the nerve cell culture area. According to the utility model, the interaction between the heart and nerve cells in the body can be more accurately simulated, and the research efficiency and quality of heart disease models and nerve disease models are improved; the method can also be used for high-throughput drug screening, and accelerates the development process of new drugs.

A method of making a biased cardiac valve including a cell configured to flex out-of-plane upon application of a lateral or circumferential force applied to the biased cell, the biased cell having an elongate member projecting axially from an apex of the biased cell that flexes out-of-plane concomitantly with out-of-plane flexion of the biased cell. A monolithic hypotube is formed into a lattice structure having a plurality of biased cells and elongate members and is configured into a cardiac valve having a main body portion, a valve leaflet portion, and a plurality of elongate biasing arm members. A polymer coating or covering is disposed on the valve leaflet portion and the elongate biasing arm members and subtends space between adjacent pairs of elongate biasing arm members to form valve leaflet cusps that are biased toward a central axis of the cardiac valve by the elongate biasing arm members.

The present technology provides compositions and methods for gene therapy and / or cell therapy for treatment of heart diseases. In particular, the present technology provides cardiac-specific promoters and vectors for expressing transgenes (e.g., large transgenes) in cardiac cells, for example, with the AAV system. The present technology also provides expression cassettes, recombinant AAV (rAAV) viral genomes, rAAV viruses or virions, pharmaceutical compositions, and methods of use in treatment or prevention of diseases (e.g., heart disease, such as cardiomyopathy).

The present invention provides recombinant adeno-associated viral vectors which are enriched in the heart but have reduced enrichment in other organs, particularly the liver and CNS cells, for use in the treatment of acquired and genetic left and right heart diseases as well as other diseases associated directly or indirectly with cardiac dysfunction.

Nucleic acid molecules comprising a first sequence encoding a cyclic nucleotide gated potassium channel or a functional fragment thereof and a second sequence encoding a chemogenetically activatable cyclic adenosine monophosphate (cAMP) generating receptor or a functional fragment thereof are provided. Expression vectors comprising the molecules, fusion proteins encoded by the molecules, cells, kits and pharmaceutical compositions are also provided. Methods of hyperpolarizing a cell, depolarizing a cardiac cell and treating a disease or condition are also provided.

The invention discloses a plant composition capable of efficiently activating anti-hypoxia activity of cardiac cells and a preparation method thereof.The preparation method comprises the steps that cardamine violifolia and rhodiola rosea are smashed and then mixed and pulped, water is added, pectinase, cellulase and hemicellulase are added for ultrasonic enzymolysis after high-pressure homogenization, centrifugal separation is performed, and a mixture is obtained; and after filtering, freezing and drying the supernate to obtain a mixed extract of cardamine violifolia and rhodiola rosea. According to the method, plant cell walls are crushed firstly through ultrahigh pressure extraction, functional components in cells are released, the functional components are dissolved in an extracting solution to the maximum extent under the action of enzymolysis and ultrasound, meanwhile, it can be guaranteed that chemical bonds of the functional components are not damaged, and the structural integrity and biological activity of the functional components are reserved to the maximum extent. The cardamine violifolia and the rhodiola rosea in the mixed extract have a synergistic effect, so that the taste of the product can be improved and the purpose of reducing the cost can be achieved under the condition that the use amount and the use period of the rhodiola rosea can be reduced.

The present invention discloses a flexible bioelectronic device for detecting the contractile function of myocardial cells and a preparation method thereof. The bioelectronic device comprises, from bottom to top, a substrate, a first film layer, a second film layer, a strain sensing system, an insulating film layer, electrodes, and a cell culture device, successfully integrating a cell culture chamber, a biosensor, and a bioreactor into one system. In the above-mentioned bioelectronic device, the strain sensing system can measure the dynamic changes of the contractile force of myocardial cells in situ; there are air channels and hollow chambers between the substrate and the first film layer, which are used for pneumatic drive of the second film layer, thereby providing mechanical stimulation to the cells; the electrodes are arranged in pairs and in contact with the cell culture device, and are used to provide electrical stimulation to the cells. The above-mentioned flexible bioelectronic device can perform high-throughput contractility measurements on myocardial cells under specified microenvironmental conditions, and has good application prospects in high-throughput cardiac drug screening and in vitro cell culture.

The present invention discloses an application of an artificially designed novel NRG-1 in disease treatment. The present invention provides a nucleic acid molecule, an NRG1 protein variant, a vector, a vaccine, a cell, a pharmaceutical composition and a protein composition. The present invention also provides the following methods: a method for producing a protein, a method for producing a primary RNA polynucleotide. The present invention also provides the following applications: application in preparing a product for preventing, alleviating or treating cardiovascular diseases, application in preparing a product for preventing, alleviating or treating neurological diseases, application in preparing a product for maintaining the normal function of cardiac cells or tissues, and application in preparing a vaccine.

The present disclosure describes ultrasound-based methods for facilitating the selective transduction of cardiac cells with therapeutic AAV vectors in vivo.

Methods and systems for cardiomyocyte maturation are generally described. In some embodiments, immature cardiomyocytes may be incubated with a three-dimensional matrix in an incubation medium and permitted to mature over a period of several weeks. In some embodiments, the three-dimensional matrix may include at least one population of microcarriers. The systems for cardiomyocyte maturation are evaluated for their scalability to meet large-scale global demand for cardiac cell therapies.

The present application relates to a novel micropeptide MP29 and a use thereof and relates to a use of the micropeptide in the preparation of a reagent or drug for preventing, treating, or alleviating diseases related to abnormal mitochondrial energy metabolism in cells, wherein the diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, aging, photoaging, fatty liver disease, liver fibrosis, liver cirrhosis, liver cancer, diabetic nephropathy, cardiovascular diseases such as heart failure, etc. By means of endogenous overexpression or exogenous synthesis, the reducing equivalents NADH in the tricarboxylic acid cycle are up-regulated to promote intracellular ATP production, thereby significantly enhancing the proliferation of high-energy-demanding cardiac cells and brain tissue cells, or suppressing oxidative damage and apoptosis of cells in Alzheimer's disease models and Parkinsonism, or alleviating hypertrophy and aging of myocardial cells in heart failure models, or ameliorating the photodamage of cells in photoaging models. These results indicate that the micropeptide MP29 has an application value in preventing or treating diseases related to abnormal mitochondrial energy metabolism.

The present technology provides compositions and methods for gene therapy and / or cell therapy for treatment of heart diseases, e.g., atrial fibrillation. In particular, the present technology provides transgenes, expression cassettes, vectors, recombinant AAV (rAAV) viral genomes, rAAV viruses or virions, and pharmaceutical compositions for overexpressing synaptopodin 2 like (SYNPO2L), isoform A (SYNPO2LA) in a cardiac cell in a subject, as well as methods of using the same in the prevention or treatment atrial fibrillation.

This disclosure provides methods to modulate cardiac regeneration in a mammalian cardiac cell or progenitor, comprising contacting the mammalian cardiac cell with a DOT1L gene modulator.

Provided herein are composition and methods for gene therapy of LEM domain-containing protein 2 (LEMD2) cardiomyopathy. Viral vectors are used to deliver LEMD2 reading frame for gene augmentation in cardiac cells that harbor loss-of-function LEMD2 mutations. A murine model for LEMD2 cardiomyopathy is also described.

This disclosure relates generally to methods of screening and preparing high purity cardiac cell therapies and related cell preparations.

The invention relates to a differentiation culture method for cardiovascular organs, which comprises the following steps: using stem cells as starting cells, respectively carrying out seven-day cardiac cell induced differentiation culture and seven-day blood vessel induced differentiation culture, mixing, carrying out fusion culture, culturing for four days, carrying out dynamic culture from eleventh day to twentieth day, and harvesting the cardiovascular organs. Deepened vascularization can be seen in the central region of the organ. Compared with the prior art, the heart-like organ and the blood vessel-like organ are combined, various heart cell types and blood vessel cell types are included, and the implementation time is shorter. Through verification, the cardiovascular organoid model with improved maturity is obtained, the central area of the obtained cardiovascular organoid has a vascularization effect of penetration growth, and multiple culture and construction prove that the cardiovascular organoid model has stability and repeatability.

The invention discloses a tissue engineering heart valve for promoting endothelialization and a preparation method and application thereof, and belongs to the technical field of biomedical materials. Comprising the following steps: S1, preparing red cell membrane vesicles RBCM-Ab; s2, preparation of the 2dDR-PLGA-NPs (2, 2 '-(2, 2'-(2, 2 S3, preparation of RBCM-Ab / 2dDR (at) PLGA (poly (lactic-co-glycolic acid)) nanoparticles; s4, preparing the decellularized heart valve DHV; s5, preparation of the tissue engineering heart valve NP-CHS-DHV (tissue engineering heart valve); by means of the method, the tissue engineering heart valve NP-CHS-DHV capable of promoting endothelialization can be obtained. According to the invention, the blood compatibility is improved, the platelet adhesion and immune recognition are reduced, and the acceleration of endothelialization is also realized. The invention provides an innovative strategy, and the endothelialization efficiency and the clinical application prospect of the tissue engineering heart valve can be remarkably improved.

A medical tool testing apparatus comprising a vessel. The vessel comprises a scaffold formed from biomaterial, live cardiac tissue, generated from cardiac cells, proliferating on the scaffold, the live cardiac tissue configured to generate electrical activity. The vessel also comprises a medical tool, in contact with live cardiac tissue, used for a medical procedure within patient anatomy. Operational features of the medical tool are determined by a visually perceptible condition of the live cardiac tissue.

The present invention discloses an endothelialization-promoting tissue-engineered heart valve and its preparation method and application, belonging to the technical field of biomedical materials. It includes the following steps: S1, preparation of red blood cell membrane vesicles RBCM-Ab; S2, preparation of 2dDR-PLGA-NPs nanoparticles; S3, preparation of RBCM-Ab / 2dDR@PLGA nanoparticles; S4, preparation of decellularized heart valve DHV; S5, preparation of tissue-engineered heart valve NP-CHS-DHV; through this method, the endothelialization-promoting tissue-engineered heart valve NP-CHS-DHV can be obtained. The present invention not only improves blood compatibility, reduces platelet adhesion and immune recognition, but also realizes the acceleration of endothelialization. The present invention provides an innovative strategy, which can significantly improve the endothelialization efficiency and clinical application prospect of tissue-engineered heart valves.

This disclosure relates generally to methods of screening and preparing high purity cardiac cell therapies and related cell preparations.

Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve β-adrenergic responsiveness.